File: Attachment THC NR - sale of strata units_Feb 12 2025.pdf

THC BIOMED INTL LTD.

P.O. Box 20033 Towne Centre Kelowna, B.C. V1Y 9H2

www.thcbiomed.com

THC BioMed Intl Ltd. Closes Sales of Strata Units

THC.CSE THCBF - OTC TFHD.F

Vancouver, Canada February 12, 2025 THC BioMed Intl Ltd. (the "Company") announces that the Company, through its wholly owned subsidiary, THC Bio Med Ltd. Inc. (the "Subsidiary"), sold four strata units in the Subsidiary's building located at 2550 Acland Road, Kelowna, British Columbia. The closing of the sale of the four strata units was completed on December 27, 2024 for an aggregate sale price of $1,400,000. Proceeds from the sale of the strata units were released on January 7, 2025. The Company used $915,169.03 of the proceeds from the sales to pay for expenses of the transactions: real estate commissions ($45,675), mortgage payout ($812,581.15), property taxes ($40,354.56), real estate fees ($6,585.04) and accounting fees ($9,973.28). The balance of the funds ($484,830.97) will be used by the Company to pay existing accounts payable and to provide working capital.

The sale price was determined by market price and negotiation with the arm's length buyer. The buyer was not a Related Person.

About THC BioMed:

THC BioMed is a leading Canadian cannabis producer dedicated to delivering high-quality cannabis products to consumers nationwide. With a focus on innovation, sustainability, and customer satisfaction, THC BioMed strives to set new standards in the cannabis industry through its commitment to excellence.

For more information, contact:

John Miller, CEO THC BioMed Intl Ltd. T: 1-844-THCMEDS E: info@thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

File: '\\swfile\EmailIn\20250212 163411 Attachment THC News Release - sale of 4 strata units_Feb 2025.doc'

THC BIOMED INTL LTD.

P.O. Box 20033 Towne Centre

Kelowna, B.C. V1Y 9H2

www.thcbiomed.com

THC BioMed Intl Ltd. Closes Sales of Strata Units

THC.CSE THCBF - OTC TFHD.F

Vancouver, Canada - February 12, 2025 - THC BioMed Intl Ltd. (the "Company") announces that the Company, through its wholly owned subsidiary, THC Bio Med Ltd. Inc. (the "Subsidiary"), sold four strata units in the Subsidiary's building located at 2550 Acland Road, Kelowna, British Columbia. The closing of the sale of the four strata units was completed on December 27, 2024 for an aggregate sale price of $1,400,000. Proceeds from the sale of the strata units were released on January 7, 2025. The Company used $915,169.03 of the proceeds from the sales to pay for expenses of the transactions: real estate commissions ($45,675), mortgage payout ($812,581.15), property taxes ($40,354.56), real estate fees ($6,585.04) and accounting fees ($9,973.28). The balance of the funds ($484,830.97) will be used by the Company to pay existing accounts payable and to provide working capital.

The sale price was determined by market price and negotiation with the arm's length buyer. The buyer was not a Related Person.

About THC BioMed:

THC BioMed is a leading Canadian cannabis producer dedicated to delivering high-quality cannabis products to consumers nationwide. With a focus on innovation, sustainability, and customer satisfaction, THC BioMed strives to set new standards in the cannabis industry through its commitment to excellence.

For more information, contact:

John Miller, CEO

THC BioMed Intl Ltd. T: 1-844-THCMEDS E: info@thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.